Is there a Bearish outlook for NeoGenomics, Inc. (NASDAQ:NEO) this week?

NeoGenomics, Inc. (NASDAQ:NEO) Logo
Investors sentiment increased to 1.6 in 2018 Q3. Its up 0.65, from 0.95 in 2018Q2. It is positive, as 12 investors sold NeoGenomics, Inc. shares while 40 reduced holdings. 36 funds opened positions while 47 raised stakes. 73.06 million shares or 16.95% more from 62.47 million shares in 2018Q2 were reported.
Schwab Charles Inv Mngmt holds 381,108 shares. Qs Invsts Ltd Liability stated it has 0% in NeoGenomics, Inc. (NASDAQ:NEO). The Ohio-based Strs Ohio has invested 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Swiss Bankshares has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 126,000 shares. Gamco Investors Et Al stated it has 190,519 shares. Penn Capital holds 0.1% in NeoGenomics, Inc. (NASDAQ:NEO) or 85,813 shares. Ubs Asset Management Americas reported 0% stake. National Bank Of Ny Mellon stated it has 0% in NeoGenomics, Inc. (NASDAQ:NEO). Franklin Inc reported 1.50M shares. Emerald Advisers Pa holds 0.94% or 1.67 million shares in its portfolio. Bluemountain Capital Mgmt Limited Liability Company has invested 0.01% in NeoGenomics, Inc. (NASDAQ:NEO). Blair William Il holds 299,044 shares or 0.03% of its portfolio. Ruggie Capital Group reported 1,350 shares. Granahan Invest Mgmt Ma reported 1.25 million shares. 1492 Cap Mngmt Ltd Liability holds 3.59% or 359,295 shares.

Since July 30, 2018, it had 1 buying transaction, and 8 sales for $208.58 million activity. $80,800 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares were sold by TETRAULT LYNN A.. SHOVLIN ROBERT J. also sold $3.68 million worth of NeoGenomics, Inc. (NASDAQ:NEO) on Friday, November 9. The insider Johnson Kevin C bought $301,600. BALLIET JENNIFER also sold $1.15M worth of NeoGenomics, Inc. (NASDAQ:NEO) shares. The insider JONES STEVEN C sold $2.85M.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 3 analysts covering NeoGenomics (NASDAQ:NEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NeoGenomics had 3 analyst reports since August 21, 2018 according to SRatingsIntel. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Outperform” rating given on Wednesday, October 31 by Raymond James. Below is a list of NeoGenomics, Inc. (NASDAQ:NEO) latest ratings and price target changes.

03/01/2019 Broker: Needham Rating: Buy New Target: $14 Initiates Coverage On
31/10/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $16 New Target: $21 Maintain
21/08/2018 Broker: Leerink Swann Rating: Outperform New Target: $18 Initiates Coverage On

The stock decreased 2.40% or $0.37 during the last trading session, reaching $14.99. About 1.71 million shares traded or 19.84% up from the average. NeoGenomics, Inc. (NASDAQ:NEO) has risen 52.35% since January 14, 2018 and is uptrending. It has outperformed by 52.35% the S&P500.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $1.42 billion. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It has a 189.76 P/E ratio. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.